Autoantibodies to Interferon in Autoimmune Polyendocrinopathy Syndrome Type 1
Author Information
Author(s): Meager Anthony, Visvalingam Kumuthini, Peterson Pärt, Möll Kaidi, Murumägi Astrid, Krohn Kai, Eskelin Petra, Perheentupa Jaakko, Husebye Eystein, Kadota Yoshihisa, Willcox Nick
Primary Institution: National Institute for Biological Standards and Control, South Mimms, United Kingdom
Hypothesis
Do patients with autoimmune polyendocrinopathy syndrome type 1 (APS1) produce autoantibodies against interferons?
Conclusion
Patients with APS1 produce high levels of autoantibodies against type I interferons, which may help in diagnosing the disease.
Supporting Evidence
- Almost all APS1 patients studied produced high levels of autoantibodies against type I interferons.
- These autoantibodies appeared early in the disease development.
- The presence of these autoantibodies may help in diagnosing APS1 even before full symptoms appear.
- Patients with APS1 had significantly higher neutralizing antibody titres compared to healthy controls.
Takeaway
Kids with a rare disease called APS1 make special antibodies that attack their own body's signals for fighting infections, which can help doctors figure out what's wrong with them.
Methodology
The study tested serum samples from APS1 patients for autoantibodies against type I interferons using binding and neutralization assays.
Limitations
The study primarily focused on Finnish and Norwegian patients, which may limit the generalizability of the findings.
Participant Demographics
Patients were primarily Finnish and Norwegian, aged between 3.3 to 57 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website